Extracellular/epidermal growth factor-like protein

Details Extracellular/epidermal growth factor-like protein Extracellular/epidermal growth factor-like protein

2005-02-08

2005-02-08

Romeo, David S. (Department: 1647)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S325000, C435S252300, C435S320100, C536S023100, C536S023500

Reexamination Certificate

active

06852506

ABSTRACT:
The present invention discloses an extracellular/epidermal growth factor polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include induction of DNA synthesis, stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders and stimulating embryogenesis and angiogenesis. Also disclosed are antagonists against such polypeptide and their use as a therapeutic to treat neoplasia. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention.

REFERENCES:
patent: 5872234 (1999-02-01), Bandman et al.
patent: 3902157 (1989-07-01), None
patent: 39 10 084 (1989-11-01), None
patent: WO 8500369 (1985-01-01), None
patent: WO9900405 (1999-01-01), None
patent: WO 9900410 (1999-01-01), None
Henikoff et al. Gene families: the taxonomy of protein paralogs and chimeras. Science. Oct. 24, 1997;278(5338):609-614.*
Wu et al. Neutralization of heparin activity by neutrophil lactoferrin. BLOOD, (Jan. 15, 1995) 85 (2) 421-8.*
Tomasetto et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma, EMBO J Feb. 1990;9(2):407-14, Jan. 1990.*
Playford et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology Jan. 1995;108(1):108-16.*
Orkin et al. Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy, issued by the National Institutes of Health, Dec. 7, 1995.*
Bowie et al. Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science, (Mar. 16, 1990) 247(4948) 1306-10.*
Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.*
George et al, “Current methods in sequence comparision and analysis,” in Macromolecular Sequencing and Synthesis, Selected Methods and Applications, 1988, D.H. Schlesinger (ed.), Alan R. Liss, Inc., New York, NY, pp. 127-149.*
Barton, “Protein sequence alignment and database scanning,” in Protein Structure Prediction, A Practical Approach, 1996 IRL Press at Oxford University Press, Oxford, UK, pp. 31-63.*
Hillier et al. GenBank. Accession No. T69538. Mar. 7, 1995.*
Brandt et al. Identification and biological characterization of an epidermal growth factor-related protein: cripto-1. Journal of Biological Chemistry,(Jun. 24, 1994) 269 (25) 17320-8.*
Hillier et al. GenBank database accesion No. N95751. US National Center for Biotechnology Inforamtion. Aug. 20, 1996.*
Hillier et al. GenBank database accesion No. W24885. US National Center for Biotechnology Inforamtion. Aug. 20, 1996.*
EMBL Database entry Hs726155; Accession Number H17726; Jul. 4, 1995 Hillier et al.: “The WashU-Merck EST Project” XP002036779.
EMBL Database entry Hs599207; Accession Number H54599; Sep. 22, 1995 Hillier et al.: “The WashU-Merck EST Project” XP002036780.
Lecka-Czernik, et al., 1995,Molecular and Cellular Biology, 15:120-128.
Smas et al., 1993,Cell, 73:725-234.
Campbell et al., 1993,Curr. Opinions in Struc. Bio., 3:385-392.
Carpenter et al., 1990,Jour. Bio. Chem.265:7709-7712.
Jurgen Engel, 1989,FEBS Letters251:1-7.
Appella et al., 1988,FEBS Letters, 231:1-4.
Welcome Bender, 1985,Cell, 43:559-560.
Alberts, B., et al., “gene” inMolecular Biology of the Cell, Third Edition, Alberts, B., et al., eds., Garland Publishing, Inc., New York, NY, p. G-10 (1994).
Appella, E., et al., “Structure and function of epidermal growth factor-like regions in proteins,”FEBS Lett.231:1-4, Elsevier Science B.V. (1988).
Doolittle, R.F., et al., “Computer-based characterization of epidermal growth factor precursor,”Nature307:558-560, Macmillan Journals Ltd. (1984).
Gibbons, G.H., and Dzau, V.J., “the Emerging Concept of Vascular Remodeling,”N. Eng. J. Med.330:1431-1438, Massachusetts Medical Society (1994).
Rao, Z., et al., “The Structure of a Ca2+-Binding Epidermal Growth Factor-like Domain: Its Role in Protein-Protein Interactions,”Cell82:131-141, Cell Press (Jul. 1995).
Ross, R., “The Pathogensis of atherosclerosis: a perspective for the 1990s,”Nature362:801-809, Macmillan Journals Ltd. (1993).
Ruoslahti, E., and Engvall, E., “Perspective Series: Cell Adhesion in Vascular Biology,”J. Clin. Invest.99:1149-1152, The American Society for Clinical Investigation, Inc. (Mar. 1997).
Selander-Sunnerhagen, M., et al., “How an Epidermal Growth Factor (EGF)-like Domain Binds Calcium. High Resolution NMR Structure of the Calcium Form of the NH2-Termianl EGF-like Domain in Coagulation Factor X,”J. Biol. Chem.267:19642-19649, The American Society for Biochemistry and Molecular Biology, Inc. (1992).
Chandler, L.P., et al., “A Monoclonal Antibody Which Inhibits Epidermal Growth Factor Binding Has Opposite Effects on the Biological Action of Epidermal Growth Factor in Different Cells,”J. Biol. Chem.260:3360-3367, American Society for Biochemistry and Molecular Biology, Inc. (1985).
Dialog File 351, Accession No. 8056852, Derwent WPI English language abstract for DE 39 10 084 A1.
Eckert, K., et al., “A Mr43,000 Epidermal Growth Factor-related Protein Purified from the Urine of Breast Cancer Patients,”Cancer Research50:642-647, American Association for Cancer Research (1990).
EMBL entry, Accession No. T27541, from Bouillaud, F. (1995).
Nakamura, T., et al., “Fibulin-5/DANCE is essential for elastogenesis in vivo,”Nature415:171-175, Macmillan Magazines Ltd. (Jan. 2002).
Schiemann, W.P., et al., “Context-specific Effects of Fibulin-5 (DANCE/EVEC) on Cell Proliferation, Motility, and Invasion,”J. Biol. Chem.277:27367-27377, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 2002).
Yanagisawa, H., et al., “Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo,”Nature415:168-171, Macmillan Magazines Ltd. (Jan. 2002).
Kowal R. C. et al., Cir. Res., vol. 84(10):1166-76 (1999).
Nakamura, T. et a., The Journal of Biol. Chem., vol. 274(32):22476-22483(1999).

Affiliated with

Also associated with

Rating

Extracellular/epidermal growth factor-like protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Extracellular/epidermal growth factor-like protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Extracellular/epidermal growth factor-like protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3513612